Monday, February 6, 2017

Glecaprevir/pibrentasvir highly effective for treating HCV genotype 1

In the Journals

Glecaprevir/pibrentasvir highly effective for treating HCV genotype 1

Poordad F, et al. Hepatology. 2017;doi:10.1002.hep.29081.
February 6, 2017

Glecaprevir/pibrentasvir was highly effective and well tolerated for the treatment of hepatitis C virus genotype 1 infection in patients who previously failed treatment with direct-acting antivirals, according to the results of the phase 2 open-label MAGELLAN-1 study.

Glecaprevir/pibrentasvir (AbbVie) is an investigational pan-genotypic regimen that combines two antiviral agents — 300 mg of glecaprevir, an NS3/4A protease inhibitor, and 120 mg of pibrentasvir, an NS5A inhibitor — that are administered once daily in three oral tablets.

Continue reading @ Healio.

Related:
Glecaprevir and Pibrentasvir for 12 Wks HCV Genotype 1 and Prior Direct-acting Antiviral Treatment
Accepted manuscript online: 27 January 2017

No comments:

Post a Comment